Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Market Closed - Nyse Other stock markets 04:00:13 2024-04-15 pm EDT			5-day change	1st Jan Change
161.7 ^USD	-0.38%		-4.79%	+4.32%

Apr. 12	AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug	MT
Apr. 12	AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	Mar. 27	MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	Mar. 22	MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing	Mar. 21	MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	Mar. 15
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	Feb. 26
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating	Feb. 06	MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating	Feb. 06	MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating	Feb. 05	MT
Morningstar Upgrades AbbVie to Hold From Sell, Increases Price Target to $168 From $137	Feb. 05	MT
Wells Fargo Adjusts Price Target on AbbVie to $200 From $180, Maintains Overweight Rating	Feb. 05	MT
Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating	Feb. 05	MT
BMO Capital Adjusts Price Target on AbbVie to $195 From $187, Maintains Outperform Rating	Feb. 05	MT
Barclays Adjusts Price Target on AbbVie to $185 From $175, Maintains Overweight Rating	Feb. 05	MT
Raymond James Adjusts Price Target on AbbVie to $189 From $181, Maintains Outperform Rating	Feb. 05	MT
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Deutsche Bank Raises AbbVie Price Target to $170 From $150, Maintains Hold Rating	Jan. 29	MT
William Blair Upgrades AbbVie to Outperform From Market Perform	Jan. 29	MT
BofA Securities Raises AbbVie Price Target to $165 From $160, Maintains Neutral Rating	Jan. 26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Analyst Reco.

Filters